Ultrasound in Assessing Antiangiogenic Treatment in Patients With Advanced Kidney Cancer

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Diagnostic procedures, such as contrast-enhanced ultrasound, may help measure a patient's response to treatment with drugs such as sunitinib malate, sorafenib tosylate, or bevacizumab, and allow doctors to plan better treatment.

PURPOSE: This clinical trial is studying ultrasonography in assessing antiangiogenic treatment in patients with advanced kidney cancer.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: National Cancer Institute, France

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of advanced renal cancer

• Planning to receive antiangiogenic treatment

• Detection of a target hepatic metastasis that is visible, located, and sized with conventional sonography and CT scan and/or MRI

PATIENT CHARACTERISTICS:

• No active cardiac disease

• No severe arterial hypertension

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics